Beyond Just ‘Eat Better’ Advice
“Eat better.” It is one of the most common pieces of advice given to people living with chronic…
Pharmacists call for medicine review program to be expanded
When fire brigade officer Colin O’Rourke left hospital after a heart procedure, he ended up on 32 different…
Novartis presents Rhapsido® (remibrutinib) data at AAAAI, showing potential beyond chronic spontaneous urticaria (CSU)
Analyses from REMIX-1 & -2 studies on CSU disease control and early symptom relief will be presented Phase…
Novartis remibrutinib first therapy to achieve Phase III primary endpoint in chronic inducible urticaria (CIndU)
Statistically significant and clinically meaningful results seen in RemIND trial with complete responses achieved in 3 CIndU types1Remibrutinib,…
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Designation based on clinical evidence supporting potential of ianalumab in Sjögren’s disease, including phase III trials1Distinction expedites development…
Your medicine is watching you — inside MIT’s new ‘smart pills’
Your medication might start tattling on you if you skip a dose. Scientists at MIT have developed a…
Novartis and US government reach agreement on lowering drug prices in the US
Novartis agrees to take actions aimed at meeting US Administration priorities for drug pricingAdditional Novartis medicines will be…
New health concern linked to chronic cannabis use
For some chronic cannabis users, a case of the munchies is the least of their problems. Over the…
‘Fake fasting’ diet can help you lose weight without starving
Research has revealed that “fake fasting” may offer the same age-reversing health benefits as forsaking food. Known as…
‘The Medical Anxiety Is Soooooo Real’
NEED TO KNOW Bella Hadid is getting candid about her ongoing battle with chronic illness In an Instagram…
Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases
Late-breaking positive Phase III data from ianalumab NEPTUNUS-1 and NEPTUNUS-2 trials in Sjögren’s disease to be presented Biomarker…
Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)
Cosentyx® (secukinumab) achieved statistically significant and clinically meaningful sustained remission vs placebo at Week 521Trial showed reduction in…